

THE VALUE-ADDED BY THE PHARMACIST : DRUG-DRUG INTERACTIONS (DDI) ANALYSIS IN MULTIDISCIPLINARY MEETING FOR HEPATITIS C

BACKGROUND : Chronic Hepatitis C management has changed tremendously with Direct Acting Antivirals (DAA) approval.

Direct Acting Antivirals : 😊 Provide a **high-sustained virological response** with **rare adverse effects**

😞 Are very **expensive**


Our health care system imposes prescription and dispensing constraints. Treatments are initiated in authorized centers thanks to **multidisciplinary meetings**

OBJECTIVES :

✓ To show how the pharmacist contributes to **DDI analysis** and to **the choice of the DAA strategy**

✓ In order to prevent **DAA loss of efficacy** and **toxicity** caused by DDI

Demand for DAA prescription



MATERIALS AND METHODS :



- ✓ Prospective analysis study of DDI on **DAA treatment access forms** over a 2 months period
- ✓ **DAA strategy proposals** and **patients' regular treatment** were systematically submitted to the analysis of the pharmacist
- ✓ DDI were identified thanks to : Hep-druginteractions.org database, Vidal monographs and a literature review

RESULTS :

- ✓ **43 patients' DAA access forms** were analyzed
- ✓ Regular therapies contained **5 drugs** on average
- ✓ **125 different drugs** were studied
- ✓ A total of **319 combinations** between DAA and regular drugs were studied

Prevalence of DDI with Direct Acting Antivirals	
Ombitasvir/paritaprevir/ritonavir	47 %
Simeprevir	40 %
Sofosbuvir/ledipasvir	16 %
Sofosbuvir/daclatasvir	13 %

Population characteristics		
Sex	Men : 58,1 %	Women : 41,8 %
HVC genotype	1 : 60 %	1a : 18,6 % 1b : 37,2 %
	Not reported : 4,65 %	
	2 : 2,3 %	
	3 : 4,7 %	
	4 : 20,1 %	
	5 : 4,7 %	
Not reported : 7,0 %		
HIV treatment (co Infection)	Yes : 28 %	No : 72 %



In this study, **contraindications** involve :

STATINS (rosuvastatin, simvastatin)
 ANTIEPILEPTICS (primidone)
 ANTIRETRVIRALS (efavirenz)
 BETA-2-AGONISTS (salmeterol)



CONCLUSION :

- ✓ This study shows that **25 %** of combinations between DAA and patients' regular drug had DDI.
- ✓ As expected, because of its metabolism, ombitasvir/paritaprevir/ritonavir association had more DDI than the other DAA.
- ✓ The pharmacist plays a key role in the DDI management and participates in the choice of hepatitis C treatment.